Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation. [electronic resource]
Producer: 20200529Description: 863-866.e5 p. digitalISSN:- 1097-6825
- Adolescent
- Anti-Inflammatory Agents -- therapeutic use
- Autoimmune Diseases -- diagnostic imaging
- Azetidines -- therapeutic use
- Brain -- diagnostic imaging
- Brain Diseases -- diagnostic imaging
- Child
- Child, Preschool
- Cytokines -- blood
- Female
- Humans
- Infant
- Janus Kinase 1 -- antagonists & inhibitors
- Janus Kinase 2 -- antagonists & inhibitors
- Magnetic Resonance Imaging
- Male
- Mutation
- Protein Kinase Inhibitors -- therapeutic use
- Purines
- Pyrazoles
- Sulfonamides -- therapeutic use
- Tomography, X-Ray Computed
- Tumor Necrosis Factor alpha-Induced Protein 3 -- genetics
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.